(EMR \$0.48) Buy



Androw Clayton	Date 28th April 2020	Price Target \$0.80/sh
Andrew Clayton	28 April 2020	\$0.80/SII


Project financing closed on track for Q2 FY'21 1st Gold

Investment case

Financial close and first debt drawdown are significant milestones for EMR, especially in these uncertain times. Okvau is now fully funded for the US\$98m capital development and importantly it remains on track for commissioning in the 2nd Q CY'21. Grade control in the oxide continues to provides some upside. Our investment thesis remains the same: backing an outstanding management team with a proven track record of development with significant 'skin in the game'. It trades well below valuation of \$0.78/sh and offers excellent leverage to a rising gold price with no hedging per se. The US\$100m acquisition facility gives clear indication that EMR will look for other projects with the aim to become a multi mine mid cap gold producer. We retain our Buy.


Key points

- US\$60m project financing facility with Sprott has closed and first draw down completed. Sprott invested a further US\$3.5m in equity @ \$0.40/sh as a contingency against any adverse movements in the exchange rate. The finance facility has also provided access to the US\$100m Acquisition and Development Facility that was previously announced.
- Now fully funded to complete Okavau construction after \$75m equity raised in Jan'20.
- In excess of US\$23m of contracts executed Outotect to supply mineral processing equipment, MACA Mining to provide contract mining services (US\$230m over 7 yrs), and start of works on Okvau electrical substation.
- Stage 1 oxide grade control completed on a 5m x 5m pattern.
 Original program of 1,200 holes extended to 1,824 holes due to additional ore defined from outside reserves as shown in the diagram below



Emerald Resources Ltd	d	Year End 30 June			
Share Price Price Target Valuation	0.45 0.80 0.772	A\$/s A\$/s A\$/s (npv 10%			
Shares on issue Market Capitalisation Enterprise Value Debt Cash Largest Shareholder	499 224 151 0 73	·	diluted * A\$m A\$m A\$m A\$m Ruffer 8%		
Production F/Cast	2020f	2021f	2022f		
Attrib. Prod'n (koz) Cash Cost (A\$/oz) Total Cost (A\$/oz)	0 593 749	27 696 906	107 724 945		
Assumptions	2020f	2021f	2022f		
Gold US\$/oz AUDUSD	1539 0.72		1600 0.65		
Key Financials	2020f	2021f	2022f		
Revenue (A\$m) EBITDA (A\$m) NPAT (A\$m) Cashflow (A\$m)	5 -5 -5 0	19 5	244 122 62 -51		
CFPS (Ac) P/CFPS (x)	0.0		-7 na		
EPS (Ac) EPS growth (%) PER (x)	0 0% 0.0	na	1 na 32.2		
EV:EBITDA (x) EV:EBIT (x)	0.0 0.0		8.0 14.8		
DPS (Ac) Dividend Yield (%)	0.0 0%		0.0 0%		
ND:Net Debt+Equity (% Interest Cover (x)	6) 0% 0.0		48% na		

Share Price Chart



Disclaimer

Euroz Securities declares that it has acted as underwriter to and/or arranged an equity issue in and/or provided corporate advice to Emerald Resources Ltd during the last year. Euroz Securities has received a fee for these services.

This analyst declares that he has a beneficial interest in Emerald Resources Ltd .

Euroz Securities Limited

All information and advice is confidential and for the private information of the person to whom it is provided and is provided without any responsibility or liability on any account whatsoever on the part of Euroz Securities Limited or any member or employee thereof. Refer to full disclaimer at the end of this document.

(EMR \$0.48) Buy



- Site access road to Okvau completed during the Q and access to project is now via a significantly improved 42km stretch of unsealed road including a new 35 tonne concrete bridge across the Prek Te River and 14km of new road to Okvau.
- Other activities included work on the substation, Okvau accommodation, village construction works and various other site infrastructure required.
- Despite potential delays due to the COVID 19, EMR has maintained guidance of commissioning in Q2 CY'21.
- WHO classifies Cambodia COVID-19 incidence rate as a 'Sporadic Case' the number of reported cases is 122 (119 recovered) with no deaths.. International travel to Cambodia is allowed with business visa and valid reason - Okvau development is deemed a valid reason. International border with Vietnam, Lao and Thailand remain open but heavily restricted to essential business related travel and trafficked goods.
- EMR expects to be able to ship goods to Cambodia during this
 restricted period. However, the above circumstances have restricted
 movements of expats mgt currently on roster at site.

Analysis

Financial close and drawdown are significant milestones for EMR as there was some risk with the uncertainty around COVID 19 this may have been delayed so its pleasing to see this occur. As we would expect, EMR has hit the ground running now that is fully funded and despite the uncertainty – particularly with the SAG mill being manufactured in Italy, it remains on schedule for commissioning in the 2nd Q CY'22.

The grade control drilling continues to provide upside surprise – identifying mineralisation outside the current envelope.

We continue to back EMR to successfully execute as one of the best 'in house development teams and a proven track record of delivery and with Directors owing 30%, interests are aligned. The US\$100m acquisition facility is a massive vote of confidence for this team to become a multi mine mid cap gold producer and hence we view Okvau as a starter project.

EMR's share price has been rangebound (3-4cps last two yrs) as the Mining Investment Agreement and financing took longer than anticipated. We would expect the stock to re rate with funding now secured – similar to what occurred at WAF and CMM.


Our valuation remains at \$0.78/sh (post 1 for 10 consolidation) based on a LT gold price of US\$1,550/oz. We note that at spot price our valuation is >\$1.00/sh.

(EMR \$0.48) Buy



Key Variables

Val	/ Sh					Gold \$				
	\$0.772	-20%	-15%	-10%	-5%	0%	5%	10%	15%	20%
	15%	\$0.44	\$0.50	\$0.57	\$0.63	\$0.69	\$0.76	\$0.82	\$0.88	\$0.95
	10%	\$0.45	\$0.52	\$0.59	\$0.65	\$0.72	\$0.78	\$0.85	\$0.92	\$0.98
SD	5%	\$0.47	\$0.54	\$0.60	\$0.67	\$0.74	\$0.81	\$0.88	\$0.95	\$1.02
AUDUSD	0%	\$0.48	\$0.55	\$0.63	\$0.70	\$0.77	\$0.85	\$0.92	\$0.99	\$1.06
PA	-5%	\$0.50	\$0.57	\$0.65	\$0.73	\$0.80	\$0.88	\$0.96	\$1.03	\$1.11
	-10%	\$0.52	\$0.60	\$0.68	\$0.76	\$0.84	\$0.92	\$1.00	\$1.08	\$1.16
	-15%	\$0.54	\$0.62	\$0.71	\$0.79	\$0.88	\$0.96	\$1.05	\$1.14	\$1.22



Our Share Price Sensitivity



Our Market Sensitivity

Valuation: \$0.083/sh Price Target: \$0.08/sh

Bull Scenario:\$0.11/sh

Mine life additions (>3yrs) at Okava and a new project for EMR to take advantage of its unique development capabilities.

Base Scenario: \$0.08/sh

Develop Okvau in line with feasibility estimates and timing with no capital cost overrun and first gold in mid CY'20.

Bear Scenario: \$0.03/sh

Political issues in Cambodia result in project delay.

Company Summary

Emerald Resources NL (EMR)is a gold exploration and development company. EMR's key asset is the Okvau Gold Project, Cambodia. Total gold reserves and resources are 907koz and 1130koz. Capital cost is estimated at US\$98m and funding via debt of US\$60m and a US\$50m equity raising is enivsiaged. First production is targeting 2nd Q CY'21.

Disclaimer

The projections and information above is based on the set assumptions outlined. Due care and attention has been used in the preparation of this information. However actual results may vary from forecasts and any variation may be materially positive or negative. Forecasts by their very nature, are subject to uncertainty and contingencies, many of which are outside the control of Euroz.

(EMR \$0.48) Buy



Market Statistics				Ve	ar End	30 June
Share Price Issued Capital FP Ord Total Dil.			S.Le n M.H n M.Ev	ectors	ar Liid	Chair MD Ex Dir NE Dir
Mkt Capital'n	\$22	4 n		tanley		NE Dir
Enterprise Value Debt Cash	\$15 \$7	5- n	n Ruff	reholders er & Mgt	5	8% 10%
Asset Valuation				A\$m		A\$/sh
Okvau gold proje Hedging/GPP Corporate Okvau Exploratio Debt				337 (27) (37) 40		0.68 (0.06) (0.07) 0.08
Cash				73		0.15
Total				385		0.772
F/Cast Production	on (A\$m)2020f	2021f	2022f	2023f	2024f
Okvau (100%)	koz	0	27	107	107	107
Avg Cash Cost Avg Total Cost Avg All in Costs	US\$/oz US\$/oz US\$/oz	593 749 n/a	696 906 733	724 945 743	725 951 744	725 955 744
Avg Spot Price Avg Price Rec'd	US\$/oz US\$/oz	1,539 1,539	1,600 1,600	1,600 1,600	1,550 1,550	1,550 1,550
Ratio Analysis (A	\\$m)	2020f	2021f	2022f	2023f	2024f
CF (A\$m) CF / Sh (Ac/sh) CF Ratio (x)		(169) (23) na	(51) (7) na	148 20 2	140 19 2	151 21 2
Earnings (A\$m) EPS (Ac/sh) EPS Growth (%) Earnings Ratio (x	`	(7) (1) na na	7 1 na 32	93 19 12 2	87 17 (0) 3	95 19 0 2
E'prise Val. (A\$m EV : EBITDA (x) EV : EBIT (x))	258 (30.3) (30.3)	296 8.0 14.8	203 1.2 1.8	113 1.3 2.0	16 1.3 1.9
Net Debt / ND+E Interest Cover (x) EBIT Margin (%) ROE (%) ROA (%)		28% na na -5% -2%	48% na 20% 6% 7%	na 32 35% 42% 44%	na na 33% 27% 33%	na na 34% 22% 26%
Div. (Ac/sh) Div. payout ratio Div. Yield (%)	(x)	- - 0%	- - 0%	- - 0%	- - 0%	- - 0%
Div. Franking (%)		0%	0%	0%	0%	0%

Profit and Loss (A\$m)	2020f	2021f	2022f	2023f	2024f		
Gold Revenue	0	65	257	244	244		
Gold Price Participation Interest Revenue	- 5	(13) 1	(13) O	(12) 3	(8) 7		
Other Revenue	-	-	-	-	-		
TOTAL REVENUE	5	53	244	236	243		
Operating Costs	0	28	116	114	114		
Dep/Amort W/O & Provisions	0	9	35 -	35 -	36 -		
Corp O/H	5	5	6	6	6		
EBITDA EBIT	(5) (5)	19 10	122 86	112 77	116 80		
Interest Expense	6	5	3	1	-		
NPBT Tax	(6) (2)	6 2	83 21	79 20	87 22		
Minorities	-	-	-	-	-		
NET PROFIT	(5)	5	62	59	65		
Net Abnormal Gain/(Los NET PROFIT After Abn'l		5	62	- 59	65		
Cash Flow (A\$m)	2020f	2021f	2022f	2023f	2024f		
Net Profit	(5)	5	62	59	65		
+ Working Capital Adj. + Dep/Amort	- 0	- 9	- 35	- 35	- 36		
+ Provisions	-	-	-	-	-		
+ Tax Expense - Tax Paid	(2)	2	21 17	20 16	22 17		
- Deferred Revenue	(1)	-	-	-	-		
Operating Cashflow	(5)	13	102	98	105		
-Capex + Development	108	47	3	3	3		
-Exploration -Assets Purchased	6	6	6	6	6		
+Asset Sales	-	-	-	-	-		
+ Other Investing Cashflow	(114)	(53)	(9)	(9)	(9)		
-		(/	(-)	(-)	(-)		
+Equity Issues +Loan D'down/Receivab	75 ole 88	-	-	-	-		
-Other (share buy back)	-	-	-	-	-		
-Loan Repayment -Dividends	-	30 -	30 -	30 -	-		
Financing Cashflow	163	(30)	(30)	(30)	-		
Period Sur (Def)	44	(70)	63	60	96		
Cash Balance	59	(11)	52	111	208		
Balance Sheet (A\$m)	2020f	2021f	2022f	2023f	2024f		
Assets Cash	59	(11)	52	111	208		
Current Receivables	5	` <u>Ś</u>	5	5	5		
Other Current Assets Non-Current Assets	10 127	10 153	10 131	10 109	10 64		
Total Assets	201	157	198	235	309		
Liabilities							
Borrowings Current Accounts Payab	92 le 5	61 5	30 5	- 5	- 5		
Other Liabilities	15	15	15	15	15		
Total Liabilities	112	81	50	20	20		
Net Assets	89	76	148	215	289		
Reserves and Resources	Reserves and Resources						
R mt	eserves g/t	koz	R mt	esource g/t	s koz		
Okvau (100%) 14.3	2.0	907	15.8	2.2	1,130		
EV per oz		167			134		

Euroz Securities Limited
All information and advice is confidential and for the private information of the person to whom it is provided and is provided without any responsibility or liability on any account whatsoever on the part of Euroz Securities Limited or any member or employee thereof. Refer to full disclaimer at the end of this document.



Disclaimer

Copyright & Distribution

The material contained in this communication (and all attachments) is prepared for the exclusive use of clients of Euroz Securities Ltd (ACN 089 314 983) ("Euroz") only. Euroz is the holder of an Australian Financial Services Licence (AFSL 243302) issued by the Australian Securities and Investments Commission ("ASIC") and is a participant of the Australian Securities Exchange Group ("ASX Group").

The information contained herein is confidential and may be legally privileged. If you are not the intended recipient no confidentiality is lost nor privilege waived by your receipt of it. Please delete and destroy all copies, and contact Euroz on (+618) 9488 1400. You should not use, copy, disclose or distribute this information without the express written authority of Euroz.

Disclaimer & Disclosure

Euroz and its associates declare that they deal in securities as part of their securities business and consequently may have a relevant interest in the securities recommended herein (if any). This may include providing equity capital market services to their issuing company, hold a position in the securities, acting as principal or agent, or make a market therein and as such may effect transactions not consistent with the recommendation (if any) in this report.

Euroz declares that it may have acted as an underwriter, arranger, co-arranger or advisor in equity capital raisings, and will have received a fee for its services, for any company mentioned within this report during the last 12 months.

You should not act on any recommendation issued by Euroz without first consulting your investment advisor in order to ascertain whether the recommendation (if any) is appropriate, having regard to your investment objectives, financial situation and particular needs. Nothing in this report shall be construed as a solicitation to buy or sell a security, or to engage in or refrain from engaging in any transaction.

Euroz believes that the information and advice contained herein is correct at the time of compilation, however we make no representation or warranty that it is accurate, complete, reliable or up to date, nor do we accept any obligation to correct or update the opinions in it. The opinions expressed are subject to change without notice. No member of Euroz accepts any liability whatsoever for any direct, indirect, consequential or other loss arising from any use of this

We cannot guarantee that the integrity of this communication has been maintained, is free from errors, virus interception or interference.

Analyst Certification

We hereby certify that all of the views expressed in this report accurately reflect our personal views about the subject company or companies and its or their

No part of our compensation was, is or will be directly or indirectly, related to the specific recommendations or views expressed by the authoring analyst in this research

Contact Details

Euroz Securities Limited

+61 8 9488 1400

Research Analysts

Jon Bishop - Head of Research Andrew Clayton - Resources Analyst Steven Clark - Resources Analyst Gavin Allen - Industrials Analyst Harry Stevenson - Industrials Analyst Seth Lizee - Associate Research Analyst

+61 8 9488 1481 +61 8 9488 1427 +61 8 9488 1430 +61 8 9488 1413 +61 8 9488 1429 +61 8 9488 1414

Institutional Sales

Andrew McKenzie - Executive Chairman +61 8 9488 1407 Rob Black - Managing Director Jay Hughes - Executive Director Russell Kane - Executive Director Simon Yeo - Executive Director Timothy Bunney - Executive Director Peter Schwarzbach - Executive Director Stacy Kitsantas - Institutional Adviser Jayme Walsh - Institutional Adviser

Private Client Advisers

Chris Webster - Head of Private Clients Ben Statham - Executive Director Brian Bates - Executive Director Cameron Murray - Executive Director James Mackie - Executive Director Lucas Robinson - Executive Director Rvan Stewart - Executive Director Tim Lyons - Executive Director Brett Stapleton - Associate Director Giles McCaw - Associate Director Michael Bowden - Associate Director Richard Gardner - Associate Director Paul Berson - Associate Director Paul Cooper - Associate Director lan Harrison - Investment Adviser Lauren Walker - Investment Adviser Michael Bartley - Investment Adviser Tom Kenny - Investment Adviser Zac Vinten - Associate Adviser Laurence Grescos - Associate Adviser Katrina Rvan - Associate Adviser Brandon Oosthuizen - Associate Adviser